Claudin 18.2 (CLDN18.2) expression prevalence, prognostication and clinical variables in gastric and gastroesophageal junction adenocarcinoma patient samples

被引：0
|
作者：
Sewastjanow, Matheus
Yamashita, Kohei
Iwata, Kenneth K.
Moran, Diarmuid
Elsouda, Dina
Pizzi, Melissa
Vicentini, Ernesto Rosa
Shanbhag, Namita
Ta, Anh
Waters, Rebecca
Chatterjee, Deyali
Ajani, Jaffer
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2141
引用
收藏
页数：3
相关论文
共 50 条
  • [41] CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC).
    Janjigian, Yelena Y.
    Shitara, Kohei
    Elimova, Elena
    Zhang, Jun
    Chen, Ming-Huang
    Smyth, Elizabeth Catherine
    Lee, Jeeyun
    Miao, Rui
    Liu, Silver
    Holmblad, Marielle
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS507 - TPS507
  • [42] CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)
    Shitara, K.
    Janjigian, Y. Y.
    Elimova, E.
    Zhang, J.
    Chen, M-H.
    Smyth, E.
    Lee, J.
    Miao, R.
    Liu, S.
    Holmblad, M.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S196 - S197
  • [43] First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
    Lei, Jianying
    Zhang, Jiahao
    You, Caicong
    Fu, Wu
    Liu, Maobai
    Li, Na
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [44] Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach
    Fassan, Matteo
    Kuwata, Takeshi
    Matkowskyj, Kristina A.
    Rocken, Christoph
    Ruschoff, Josef
    MODERN PATHOLOGY, 2024, 37 (11)
  • [45] Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).
    Qi, Changsong
    Liu, Chang
    Gong, Jifang
    Li, Jian
    Liu, Dan
    Ge, Sai
    Zhang, Miao
    Peng, Zhi
    Zhou, Jun
    Zhang, Xiaotian
    Zheng, Ji
    Xiao, Jun
    Yuan, Daijing
    Peng, Yueying
    Wang, Huamao
    Li, Zonghai
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study
    Yu, X.
    Zhang, J.
    Liu, J. J.
    Yang, J.
    Yue, J.
    Sun, Y.
    Pan, Y.
    Sun, M. L.
    Qin, Y.
    Shen, L.
    Song, R.
    Ruan, J.
    Zhou, A.
    Mou, Y.
    Aghmesheh, M.
    Morris, M.
    Yu, X.
    Zhao, X.
    Chen, M.
    Tazbirkova, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
  • [47] Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
    Rohde, Christoph
    Yamaguchi, Rin
    Mukhina, Svetlana
    Sahin, Ugur
    Itoh, Kyogo
    Tuereci, Oezlem
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (09) : 870 - 876
  • [48] Safety and efficacy of zolbetuximab for CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Celso, Davi Said Goncalves
    Reis, Pedro Cotta Abrahao
    Escalante-Romero, Lorena
    Dacoregio, Maria Inez
    Gomy, Israel
    Marin Comini, Ana Carolina
    Camandaroba, Marcos Pedro Guedes
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 370 - 370
  • [49] CLDN18/CLDN18.2 IHC assay comparison (SP455, 43-14A, EPR19202) and co-prevalence expression with other biomarkers in gastric carcinoma
    Clements, Miranda E.
    Willis, Sophie E.
    Korade, Martin, III
    Ortiz, Lorenzo
    Zalesak-Kravec, Stephanie
    Lombard, Cam
    Richardson, Chris
    Chambers, Andrew
    Kim, Yeoun Jin
    Tsao, Tsu-Shuen
    Robida, Mark
    Zaucha, Jan
    Berry, Deborah
    Jones, Gemma N.
    Barrett, Allison
    Durham, Nick
    Rebelatto, Marlon
    Broggi, Maria
    Thress, Kenneth S.
    Giraldo, Nicolas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials
    Lordick, F.
    Van Cutsem, E.
    Shitara, K.
    Xu, R. -H.
    Ajani, J. A.
    Shah, M. A.
    Oh, M.
    Ganguli, A.
    Chang, L.
    Rhoten, S.
    Bhattacharya, P.
    Matsangou, M.
    Park, J. W.
    Pophale, R.
    Ranganath, R.
    Kang, Y. -K.
    ESMO OPEN, 2024, 9 (08)
12345